Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ANS014004 in Advanced Solid Tumors
NCT06307795Phase 1Recruiting
- Sponsor
- Avistone Biotechnology Co., Ltd.
- Start
- Jun 2024
- Primary completion
- Apr 2027
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 3
01
Overview
Phase 1, open-label, single-arm trial of ANS014004 in solid tumor, sponsored by Avistone Biotechnology Co., Ltd. Primary endpoints: Incidence of Adverse Events, Incidence of Serious Adverse Events and 3 more. Started Jun 2024; status: recruiting.
02
Drugs
ANS014004
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06307795.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06307795.